Exelixis, Inc. (NASDAQ:EXEL) Given Average Recommendation of “Hold” by Brokerages
Exelixis, Inc. (NASDAQ:EXEL) has received an average recommendation of “Hold” from the twelve brokerages that are covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $24.38.
Several equities research analysts recently commented on EXEL shares. Bank of America assumed coverage on shares of Exelixis in a research report on Wednesday, November 13th. They issued a “buy” rating and a $22.00 price objective on the stock. BMO Capital Markets decreased their target price on shares of Exelixis from $23.00 to $19.00 and set a “market perform” rating for the company in a research report on Tuesday, October 8th. TheStreet downgraded shares of Exelixis from a “b-” rating to a “c” rating in a research report on Friday, November 22nd. Zacks Investment Research lowered Exelixis from a “hold” rating to a “sell” rating and set a $19.00 price target on the stock. in a research report on Thursday, October 3rd. Finally, BidaskClub cut Exelixis from a “hold” rating to a “sell” rating in a research note on Wednesday, August 28th.
Shares of EXEL traded up $0.95 on Friday, hitting $17.62. The company’s stock had a trading volume of 184,030 shares, compared to its average volume of 2,574,346. The firm’s fifty day moving average price is $16.46 and its 200-day moving average price is $19.11. Exelixis has a fifty-two week low of $15.02 and a fifty-two week high of $25.31. The company has a quick ratio of 6.80, a current ratio of 6.89 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $5.05 billion, a price-to-earnings ratio of 12.33, a P/E/G ratio of 2.19 and a beta of 1.78.
In related news, CMO Gisela Schwab sold 50,000 shares of Exelixis stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $15.99, for a total transaction of $799,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Michael Morrissey sold 37,227 shares of Exelixis stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $19.20, for a total transaction of $714,758.40. The disclosure for this sale can be found here. In the last 90 days, insiders sold 144,894 shares of company stock worth $2,539,716. 4.50% of the stock is owned by company insiders.
Institutional investors have recently added to or reduced their stakes in the business. Maverick Capital Ltd. bought a new stake in shares of Exelixis during the third quarter worth approximately $943,000. Man Group plc raised its position in shares of Exelixis by 169.8% in the third quarter. Man Group plc now owns 422,493 shares of the biotechnology company’s stock valued at $7,472,000 after buying an additional 265,894 shares in the last quarter. Squarepoint Ops LLC raised its position in shares of Exelixis by 174.7% in the third quarter. Squarepoint Ops LLC now owns 305,778 shares of the biotechnology company’s stock valued at $5,408,000 after buying an additional 194,446 shares in the last quarter. Public Employees Retirement System of Ohio raised its position in shares of Exelixis by 2.7% in the third quarter. Public Employees Retirement System of Ohio now owns 215,062 shares of the biotechnology company’s stock valued at $3,803,000 after buying an additional 5,635 shares in the last quarter. Finally, Point72 Asset Management L.P. bought a new stake in shares of Exelixis in the third quarter valued at approximately $2,012,000. 77.03% of the stock is currently owned by hedge funds and other institutional investors.
Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.
Read More: 52-Week Highs and Lows
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.